Photophobia and drugs of ingredients of abatacept - a phase IV clinical study of FDA data


Summary:

Photophobia is found among people who take drugs with ingredients of abatacept, especially for people who are female, 40-49 old , have been taking the drugs for 1 - 6 months. This phase IV clinical study is created by eHealthMe based on reports of 139,726 people who have side effects when taking drugs with ingredients of abatacept from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Orencia.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.


On Nov, 21, 2022

139,726 people reported to have side effects when taking drugs with ingredients of abatacept.
Among them, 112 people (0.08%) have Photophobia


What is Photophobia?

Photophobia (extreme sensitivity to light) is found to be associated with 2,309 drugs and 1,693 conditions by eHealthMe.

Number of reports submitted per year:

Could drugs with ingredients of abatacept cause Photophobia?

Time on drugs with ingredients of abatacept when people have Photophobia *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 100 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Photophobia when taking drugs with ingredients of abatacept *:

  • female: 95.05 %
  • male: 4.95 %

Age of people who have Photophobia when taking drugs with ingredients of abatacept *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 1.1 %
  • 30-39: 1.1 %
  • 40-49: 46.15 %
  • 50-59: 7.69 %
  • 60+: 43.96 %

Conditions people have *:

  1. Pain: 6 people, 5.36%
  2. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 1.79%
  3. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 1.79%
  4. Migraine (headache): 2 people, 1.79%
  5. Ankylosing Spondylitis (type of arthritis affecting the spine): 2 people, 1.79%
  6. Small Intestine Ulcer: 1 person, 0.89%
  7. Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 1 person, 0.89%
  8. Inflammation: 1 person, 0.89%
  9. Headache (pain in head): 1 person, 0.89%
  10. Gastric Ulcer (stomach ulcer): 1 person, 0.89%

Other drugs people take *:

  1. Enbrel: 90 people, 80.36%
  2. Humira: 82 people, 73.21%
  3. Remicade: 66 people, 58.93%
  4. Actemra: 63 people, 56.25%
  5. Plaquenil: 56 people, 50.00%
  6. Celebrex: 44 people, 39.29%
  7. Cimzia: 44 people, 39.29%
  8. Codeine: 42 people, 37.50%
  9. Xeljanz: 41 people, 36.61%
  10. Septra: 41 people, 36.61%

Other side effects people have besides Photophobia *:

  1. Pain: 79 people, 70.54%
  2. Eye Pain: 78 people, 69.64%
  3. Drug Ineffective: 77 people, 68.75%
  4. Nausea (feeling of having an urge to vomit): 75 people, 66.96%
  5. Fatigue (feeling of tiredness): 69 people, 61.61%
  6. Haemoglobin Decreased: 68 people, 60.71%
  7. Inflammation: 59 people, 52.68%
  8. Drug Intolerance (drug sensitivity): 55 people, 49.11%
  9. Malaise (a feeling of general discomfort or uneasiness): 51 people, 45.54%
  10. White Blood Cell Count Decreased: 50 people, 44.64%

* Approximation only. Some reports may have incomplete information.


How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drugs with ingredients of abatacept, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on abatacept. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: